This patient showed a combination of proximal muscle weakness and a great excess of triglyceride in type 1 muscle fibres. He did not develop muscle pain on exercise, his plasma lipid concentrations were normal, and he could produce ketones on fasting. This syndrome accords with previous descriptions of the clinical features of the lipid storage myopathy associated with carnitine deficiency.8 12 Spontaneous remissions have been reported in this condition,'2 but in view of our patient's 12-year history of continuous profound muscle weakness with persistently raised activities of creatine kinase and lactate dehydrogenase it seems unlikely that treatment with propranolol coincided with a spontaneous remission in his case.
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Results
The mean serum vitamin A concentration in patients with chronic renal failure (4 8 ± 1 8 ,umol/l (136 2±50 5 jig/100 ml)) was significantly higher (p<0001) than that in controls (1-8±04 l±mol/l (51 9±11-9 [Lg/100 ml)) (fig 1) . There was a statistically significant correlation between serum vitamin A concentrations and plasma calcium concentrations (r=0034, p<005), but vitamin A concentrations did not correlate with age, duration of dialysis, plasma phosphate, alkaline phosphatase, hydroxyproline, or immunoreactive parathyroid hormone concentrations. The mean vitamin A concentration in patients taking multivitamins (5 2 ± 1 9 tmol/l (150 0 ± 54 0 [Lg/100 ml)) was significantly higher (p < 0-05) than in those not taking the preparation (3 9 ±13 .omol/l (112-6±36-0 ,ug/100 ml)).
Eighteen patients were hypercalcaemic and these patients had a significantly higher (p <0 005) mean serum vitamin A concentration (5 6±2-1 [Lmol/l (160 5±59-0 ,ug/100 ml)) than normocalcaemic patients (4 0±1-3 t±mol/l (114-4±36 0 [±g/100 ml)) (fig 2) . There higher than values found in controls (p <001). There was a concomitant fall in plasma calcium concentrations, which was also significant (p < 0 01) at two and three months. Six hypercalcaemic patients undergoing haemodialysis.
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Discussion
We found raised serum concentrations of vitamin A in patients with chronic renal failure who were undergoing haemodialysis, which agrees with previous findings.'-3 Factors that may contribute to the high vitamin A concentrations in these patients are diminished metabolism of retinol to retinoic acid, which is a function of the kidney,'5 and increased concentrations of retinol-binding protein found in chronic renal failure.'
The significantly higher serum vitamin A concentrations in patients taking vitamin A supplements and the significant fall in serum vitamin A concentrations on withdrawal of vitamin A supplements indicate that these agents make an important contribution to vitamin A toxicity. The recommended daily requirement for vitamin A in adults is 5000 IU, these patients were taking up to 15 000 IU daily in addition to dietary vitamin A. Although this level of intake would be unlikely to produce problems in patients with normal renal function, care should be taken in the prescribing of such preparations to patients with impaired renal function.
We also found a positive correlation between serum vitamin A concentrations and plasma calcium concentrations in patients with chronic renal failure, in agreement with others.'6 The significantly higher concentrations of vitamin A in hypercalcaemic patients than in normocalcaemic patients and the significant reduction in plasma calcium concentration that occurred after withdrawal of vitamin A supplements indicate that vitamin A toxicity contributes to hypercalcaemia in patients undergoing haemodialysis. Hypercalcaemia is a well-documented effect of chronic vitamin A overdose in man and occurred in the presence of similar concentrations of vitamin A to those found in this study.8--10 Since each Multivite tablet also contains a small amount of vitamin D2 (250 IU) this might have contributed to the hypercalcaemia in these patients. This, however, is unlikely since such small quantities of vitamin D, are insufficient to overcome the "vitamin-D resistance" of chronic renal failure.'7 18 The mechanism by which hypervitaminosis A causes hypercalcaemia is far from clear. In tissue culture experiments vitamin A has been shown to produce osteolysis4 5 and to potentiate the osteolytic action of parathyroid extract.5 In the rat hypervitaminosis A causes increased bone resorption6 7 and, at least in the rapidly growing animal, may produce an inhibition of osteoblastic activity. 7 19 These osteolytic effects may occur as the result of the effect of vitamin A on lysosomal membranes.20 21 In man skeletal lesions, radiological evidence of hyperostosiS,22
and histological evidence of osteolysis23 have been described in hypervitaminesis A. Vitamin A has also been shown to stimulate parathyroid hormone secretion both in bovine parathyroid tissue and in man. 24 We found no correlation between vitamin A concentrations and any of the radiological and histological variables of bone disease studied. The significant reduction in alkaline phosphatase activity which occurred on withdrawal of vitamin A suggests that the high concentrations of vitamin A were having an effect on bone, though we found no change in hydroxyproline concentrations. No change in immunoreactive parathyroid hormone concentration occurred after withdrawal of vitamin A, in spite of the significant reduction in plasma calcium concentration, which may have been expected to cause a rebound rise in plasma immunoreactive parathyroid hormone concentration. This may reflect a summation of effects of vitamin A on both parathyroid and bone. Alternatively, vitamin A may increase the sensitivity of bone cells to the osteolytic action of parathyroid hormone.
In conclusion, it appears that the high serum vitamin A concentration that occurs in patients with chronic renal failure has toxic effects. Hypercalcaemia probably occurs as a consequence of the effect of vitamin A on bone, though further work is necessary to establish the precise mechanisms.
